REX Shares launches peptide ETF on Nasdaq under ticker PEPT
The fund tracks the VettaFi Peptide Index, which had 36 constituents as of September 30, and charges a 0.65 per cent expense ratio.
TR
By Tom Reyes · Markets Editor
Oct 20 03:37 ETSource: The Armchair Trader
The wire
- 01REX Shares listed the REX Peptide ETF on Nasdaq, investing across drug developers, manufacturers, medical devices, nutraceuticals and cosmeceuticals rather than only Eli Lilly and Novo Nordisk.
- 02CEO Greg King said the next phase of growth runs through companies that develop, make and deliver peptides, citing manufacturing capacity as a constraint on supply.
- 03REX cited JPMorgan estimates of a $200bn incretin market by 2030 and Morgan Stanley forecasts of $190bn by 2035; such projections are sponsor-selected and unverified.
From the source
Read at thearmchairtrader.comREX launches peptide ETF to go beyond GLP-1 drugmakers
REX Shares has launched a thematic exchange-traded fund targeting the peptide industry, seeking to broaden investor exposure to the booming market for GLP-1 weight-loss treatments beyond its two dominant pharmaceutical companies.
